secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001213900-25-017656
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics reports FY2024 net loss of $71.3M; briquilimab data positive
--------------------------------------------------------------------------------

- Cash and equivalents $71.6M at Dec 31, 2024; net loss $71.3M ($4.89 diluted EPS) for FY2024.
- BEACON study in CSU: multiple dosing regimens ≥120mg showed >25-point UAS7 improvement; Phase 2b expected H2 2025.
- SPOTLIGHT study in CIndU: 14 of 15 patients (93%) achieved clinical response; 83% complete response in 120mg cohort.
- First patient dosed in ETESIAN asthma study; initial data expected H2 2025.
- Open-label extension study commenced; initial data from ~30 patients expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025017656/0001213900-25-017656-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025017656/ea0232349-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-017656

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer